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Abstract MyD88 is an adapter protein that is involved in Toll-
like receptor (TLR)- and interleukin-1 receptor (IL-1R)-induced
activation of nuclear factor-UB (NF-UB) and c-Jun N-terminal
kinase (JNK). By directly binding IL-1R-associated kinase
(IRAK)-1 and IRAK-4, MyD88 serves as a bridging protein,
enabling IRAK-4-induced IRAK-1 phosphorylation. We previ-
ously identi¢ed a lipopolysaccharide-inducible splice variant of
MyD88, MyD88S, which speci¢cally prevents the recruitment of
IRAK-4 into the IL-1R complex and thus inhibits IRAK-4-
mediated IRAK-1 phosphorylation. MyD88S is not able to ac-
tivate NF-UB, and in contrast functions as a dominant negative
inhibitor of TLR/IL-1R-induced NF-UB activation. Unexpect-
edly, we here demonstrate that MyD88S still allows JNK phos-
phorylation and activator protein (AP)-1-dependent reporter
gene induction upon overexpression in HEK293T cells. These
observations indicate that NF-UB and JNK activation pathways
can already diverge at the level of MyD88. Moreover, the regu-
lated expression of a MyD88 splice variant which speci¢cally
interferes with NF-UB- but not AP-1-dependent gene expression
implies an important role for alternative splicing in the ¢ne-
tuning of TLR/IL-1R responses.
7 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
MyD88 is a universal adapter protein for members of the
Toll-like receptor/interleukin-1 receptor (TLR/IL-1R) super-
family (reviewed in [1]). TLR/IL-1Rs are a group of evolutio-
narily conserved receptors that coordinate the innate immune
response and are characterized by the presence of a so-called
Toll/IL-1R (TIR) motif in their intracellular domain. Whereas
IL-1R signaling seems to be speci¢cally mediated by MyD88
[2], several TLRs also require other adapter molecules, Mal
(also named TIRAP) or TRIF (also named TICAM-1) [3^6],
for downstream signaling. MyD88 or MyD88-like adapters
couple to several members of the IL-1R-associated kinase
(IRAK) family (reviewed in [7]). Through its C-terminal
TIR domain and its N-terminal death domain, MyD88 links
receptors of the TLR/IL-1R family with IRAK-1 [8]. Via its
intermediate domain (ID), MyD88 also recruits IRAK-4 and
in this way mediates close association of the two IRAK family
members [9]. This enables IRAK-4 to phosphorylate IRAK-1,
which is probably the initial trigger to activate IRAK-1Ps own
kinase activity and IRAK-1 hyperphosphorylation [10]. Phos-
phorylated IRAK-1 then interacts with tumor necrosis factor
(TNF) receptor-associated factor 6 (TRAF6), which further
transmits a signal leading to activation of the IUB kinase
complex and c-Jun N-terminal kinase (JNK) [11]. This even-
tually results in enhanced transcriptional activity of nuclear
factor-UB (NF-UB) and activator protein-1 (AP-1) transcrip-
tion factors. It is generally accepted that activation of NF-UB-
and AP-1-dependent gene transcription upon TLR/IL-1R trig-
gering strongly contributes to the development of the innate
immune response.
We previously identi¢ed a lipopolysaccharide (LPS)-induc-
ible splice variant of MyD88, MyD88S, which lacks the ID
[12]. MyD88S prevents recruitment of IRAK-4, but not
IRAK-1, into the receptor complex and therefore does not
allow IRAK-4-mediated IRAK-1 phosphorylation [9]. As a
result, MyD88S exerts a dominant negative e¡ect on LPS-
and IL-1-induced NF-UB activation, whereas TNF-induced
NF-UB activation is una¡ected [12]. In the present study, we
show that MyD88S still induces JNK activation and AP-1-
dependent gene expression, suggesting an important role for
alternative splicing in the ¢ne-tuning of TLR/IL-1R signaling.
2. Materials and methods
2.1. Cell culture and biological reagents
HEK293T cells were grown in Dulbecco’s modi¢ed Eagle’s medium
(DMEM), supplemented with 10% fetal calf serum, 2 mM L-gluta-
mine, 100 U/ml penicillin, 100 Wg/ml streptomycin, 1 mM sodium
pyruvate, and 50 WM 2-mercaptoethanol. HEK293-mycIL1RI cells,
stably expressing Myc-IL1RI, were grown in DMEM/NutMixF12
(with pyridoxine and glutamax), supplemented with 2% fetal calf se-
rum, 100 U/ml penicillin and 100 Wg/ml streptomycin. Recombinant
murine IL-1L was produced by Escherichia coli and puri¢ed to at least
99% homogeneity. The IL-1L preparation used had a speci¢c biolog-
ical activity of 3.65U108 IU/mg puri¢ed protein, as determined with
the international standard (code 93/668; National Institute for Bio-
logical Standards and Control, Potters Bar, UK).
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2.2. Expression vectors
pCAGGS-E-MyD88L, pCAGGS-E-MyD88S and pCRIII-MyD88-
lpr (MyD88 with point mutation F56N) have been described previ-
ously [9,12]. pCDNA3-AU1-MyD88-TIR(152^296) was a generous
gift of Dr. M. Muzio (Mario Negri Institute, Milan, Italy) and has
been described elsewhere [13]. pNFconluc, containing the luciferase
reporter gene driven by a minimal NF-UB responsive promoter, was a
gift of Dr. A. Israel (Institut Pasteur, Paris, France). pactLgal, con-
taining the L-galactosidase gene after the L-actin promoter, was ob-
tained from Dr. Inoue (Institute of Medical Sciences, Tokyo, Japan).
An AP-1-dependent luciferase reporter construct, pAP-1luc, was pur-
chased from Stratagene (PathDetect System). pJNK1-Flag was ob-
tained from Christian Widmann (Denver, CO, USA).
2.3. Transient transfection and NF-UB and AP-1 reporter gene assays
HEK293T and HEK293-IL1RI cells were transiently transfected by
the DNA calcium phosphate precipitation method with 100 ng
pNFconluc or 100 ng pAP-1luc, 100 ng pactLgal and di¡erent con-
centrations of speci¢c MyD88 expression plasmids. The total amount
of DNA was kept constant by adding empty vector up to 1 Wg DNA
per well in a six-well plate. NF-UB and AP-1 activity was determined
by measuring the luciferase activity present in cell extracts. Luciferase
values were normalized for di¡erences in transfection e⁄ciency on the
basis of L-galactosidase activity in the same extracts, and expressed as
fold induction values relative to the unstimulated empty vector con-
trol. In parallel, cell extracts of the same transfections were separated
on sodium dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^
PAGE), and immunoblotted to assess expression levels of the trans-
fected proteins.
2.4. Western blotting
Protein lysates were prepared in RIPA bu¡er (25 mM Tris, pH 8.2,
50 mM NaCl, 0.5% NP-40, 0.5% deoxycholic acid, 0.1% SDS, 10 WM
iodoacetate) supplemented with protease and phosphatase inhibitors.
Lysates were analyzed by 10% SDS^PAGE and Western blotting.
Antibodies used were anti-MyD88 (Immucor, Roedermark, Ger-
many), anti-Flag/M2 (Sigma, St. Louis, MO, USA), anti-phos-
phoJNK (Cell Signaling, Beverly, MA, USA), anti-JNK (Cell Signal-
ing) and anti-AU1 (Eurogentec, Seraing, Belgium).
3. Results
3.1. MyD88S di¡erentially a¡ects AP-1- and
NF-UB-dependent gene expression
We previously demonstrated that MyD88S is no longer able
to activate NF-UB-dependent gene expression [12]. In the
present study, we analyzed the ability of MyD88S to activate
AP-1-dependent gene expression. Therefore, di¡erent concen-
trations of MyD88L and MyD88S expression plasmids were
cotransfected with an AP-1-dependent luciferase reporter gene
construct in HEK293T cells. An earlier described mutant of
MyD88, MyD88-TIR, which only encodes the TIR domain
and activates neither JNK nor NF-UB [8,14], was also tested
as a control. Proper expression of the di¡erent MyD88 con-
structs was evaluated on Western blot (Fig. 1A,B, lower pan-
els). In line with previous data [14], overexpression of
MyD88L induced AP-1 reporter gene expression (Fig. 1A).
Interestingly, MyD88S also induced AP-1 activation in a
dose-dependent way, whereas MyD88-TIR did not. In con-
trast, and as previously described [12], MyD88S was unable to
activate NF-UB-dependent gene expression (Fig. 1B). These
results demonstrate that in contrast to MyD88L, MyD88S
speci¢cally induces AP-1-dependent gene expression, suggest-
ing that in HEK293T cells NF-UB and AP-1 activation path-
ways can diverge early in the TLR/IL-1R signaling pathway.
3.2. MyD88S and MyD88L induce JNK phosphorylation
Since AP-1 is regulated by JNK, the above observations
suggest that MyD88S still activates the JNK pathway. There-
fore, we investigated if MyD88S was still able to activate JNK
phosphorylation. We cotransfected a Flag-tagged expression
vector for JNK1 with expression plasmids for MyD88L,
MyD88S or MyD88-TIR, and analyzed JNK phosphorylation
by immunoblotting with phospho-JNK-speci¢c antibodies.
We were unable to detect phosphorylation of endogenous
JNK (data not shown). Both in the presence of MyD88L
and in the presence of MyD88S, a marked induction of phos-
phorylated JNK could be observed, although MyD88L proved
to be a more potent activator (Fig. 2A, upper panel). In con-
trast, MyD88-TIR did not induce JNK phosphorylation.
In line with these observations, IL-1-induced JNK phos-
phorylation was not a¡ected by co-expression of MyD88S
or MyD88L (Fig. 2B). In contrast, co-expression of MyD88-
TIR or MyD88-lpr (a F56N mutant that corresponds to the
site that is mutated in the Fas-lpr receptor and disrupts the
proper folding of the death domain [14]) strongly interfered
with IL-1-induced JNK phosphorylation. Thus, in contrast to
its dominant negative e¡ect on IL-1-induced NF-UB activa-
Fig. 1. E¡ect of MyD88S and MyD88L on AP-1- and NF-UB-de-
pendent gene expression. HEK293T cells were transiently transfected
with an AP-1-dependent luciferase reporter plasmid (A) or an NF-
UB-dependent luciferase reporter plasmid (B) in the absence or pres-
ence of increasing concentrations (100^500 ng) of MyD88S,
MyD88L, MyD88-TIR or empty vector (EV) as indicated. Lucifer-
ase activity in cell extracts was normalized for di¡erences in trans-
fection e⁄ciency on the basis of L-galactosidase activity, resulting
from the co-expression of the L-galactosidase reporter plasmid
pactLgal. Values are the mean (N S.E.M.) of three di¡erent transfec-
tions within a single experiment, and are expressed as fold induction
relative to the EV control. In parallel, cell extracts were assayed for
proper expression of the di¡erent MyD88 constructs by Western
blotting (lower panel of A and B).
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tion [12], MyD88S has no e¡ect on IL-1-induced JNK activa-
tion and AP-1-dependent gene expression.
4. Discussion
In the present study, we demonstrated that MyD88S, a
splice variant of MyD88, still induces JNK phosphorylation
and AP-1-dependent reporter gene expression upon overex-
pression, while being unable to activate NF-UB-dependent re-
porter gene expression. In line with these data, MyD88S did
not interfere with IL-1-induced JNK phosphorylation. In this
way, MyD88S behaves very di¡erently from MyD88-TIR, an
earlier described dominant negative mutant of MyD88, which
abrogates both IL-1-induced NF-UB and JNK activation [8].
MyD88S is not constitutively expressed, but can be induced by
LPS treatment in monocytes [12]. Therefore, our present ob-
servations suggest that the regulated expression of MyD88S
enables a cell to ¢ne-tune TLR/IL-1R-dependent signaling,
interfering speci¢cally with one of the two major downstream
signaling cascades, while leaving the other intact. Further-
more, they also suggest that deletion of the ID in MyD88,
and thus interference with IRAK-1 phosphorylation [9,12],
does not abolish the capacity of MyD88 and IRAK-1 to sig-
nal to JNK. This is in agreement with earlier observations of
Li et al. [15], who demonstrated by means of reconstitution
experiments in IRAK-1-de¢cient cells that phosphorylation of
IRAK-1, and thus binding to TRAF6, is essential for activa-
tion of NF-UB, whereas it is dispensable for IL-1-induced
JNK activation. These data are quite unexpected in view of
the previous observation that TRAF6-de¢cient MEF cells
are completely defective in IL-1-induced JNK and NF-UB
activation [16]. The latter observation suggested that JNK
and NF-UB pathways diverge downstream of TRAF6, most
likely at the level of the TRAF6 binding proteins ECSIT and
TAB [17,18]. However, we speculate that TRAF6 might be
recruited to the IL-1R in an alternative way, which involves
its N-terminal domain and which is su⁄cient for activation of
MAP3Ks and JNK, but not NF-UB (Fig. 3). This is also
supported by the fact that di¡erent domains of TRAF6 are
needed for IL-1-induced JNK and IL-1-induced NF-UB acti-
vation, respectively, as revealed by restoration experiments
with TRAF6 deletion mutants in TRAF6-de¢cient MEF cells
[19]. How IRAK-1 and IRAK-4 are implicated in this alter-
native mechanism of TRAF6 recruitment and activation is not
yet known, but IRAK-1 might be needed for stabilization of
the complex, or might indirectly mediate TRAF6 recruitment.
It is important to note that gene disruption of IRAK-4 abro-
gated both the IL-1-induced NF-UB and JNK signaling [20],
suggesting an essential function of IRAK-4-mediated phos-
phorylation in both pathways. However, one cannot rule
out the existence of other IRAK-4 targets that are essential
for JNK activation, but which do not require the binding of
IRAK-4 to MyD88.
We previously hypothesized a role for MyD88S expression
in the development of endotoxin tolerance [12]. This is further
supported by our present ¢nding that MyD88S di¡erentially
regulates NF-UB and mitogen-activated protein kinase
(MAPK) activation, since a recent report showed that mono-
cytes from trauma patients have an impaired NF-UB response
to E. coli LPS, while their p38 MAPK response is fully intact
[21]. In contrast, however, several other studies have shown
that NF-UB as well as MAPK signaling pathways are blunted
in endotoxin-tolerant cells (for review see [22]), suggesting that
other molecules than MyD88S can also contribute to the de-
velopment of endotoxin tolerance.
It has recently been proposed that the balance between
JNK and NF-UB activation is critical for the decision between
life and death, i.e. NF-UB activation provides a strong anti-
apoptotic signal due to the activation of cell survival genes
and to the inhibition of the JNK signaling pathway. Inhibi-
tion of the NF-UB pathway was shown to result in a pro-
longed JNK activation and the induction of apoptosis upon
stimulation with TNF [23,24]. In view of the speci¢c inhibi-
tion of IL-1-induced NF-UB activation by MyD88S, it could
be expected that MyD88S overexpression sensitizes cells to IL-
1-induced apoptosis. However, we were unable to demon-
strate a pro-apoptotic e¡ect of IL-1 in cells overexpressing
MyD88S (data not shown). In fact, this is in agreement with
the ¢nding of Tang and colleagues, who demonstrated that
Fig. 2. E¡ect of MyD88S and MyD88L on JNK phosphorylation.
HEK293T (A) or HEK293-IL1RI (B) cells were transfected with a
vector encoding Flag-JNK1 together with expression plasmids for
MyD88S (100 ng in A; 100, 200 or 500 ng in B), MyD88L (100 ng
in A and B), MyD88-TIR (100 ng in A; 100, 200 or 500 ng in B),
MyD88-lpr (100 or 200 ng in B), or empty vector (EV; 100 ng in
A; 500 ng in B) as indicated. In B, cells were treated 48 h after
transfection with 100 ng/ml IL-1L for the times indicated. Cell ex-
tracts were assayed for JNK phosphorylation by Western blotting
with phospho-JNK-speci¢c antibodies (upper panels). In parallel,
blots were probed for total JNK and MyD88 variants (lower pan-
els).
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the cross-talk between NF-UB and JNK is speci¢c for the
TNF response, and does not hold for the response to IL-1
[24].
In conclusion, although the underlying mechanism and the
physiological relevance for the di¡erential modulation of NF-
UB and JNK activation by MyD88S remains unclear, our ob-
servations suggest that the regulated expression of MyD88S
allows a cell to modulate its transcriptional response to spe-
ci¢c environmental stimuli.
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